SOURCE: Galapagos NV

October 22, 2010 06:09 ET

Galapagos completes private placement by issuance of 2,389,347 new ordinary shares

MECHELEN, BELGIUM--(Marketwire - October 22, 2010) -

Galapagos NV (Euronext: GLPG) announces that it has completed its capital increase by issuing today 2,389,347 new ordinary shares. These shares will be delivered to Belgian and international institutional and other eligible investors who participated in the EUR28.7 million private placement closed earlier this week. The newly issued shares will be admitted to listing on NYSE Euronext Brussels/Amsterdam on 25 October 2010.

Galapagos has a total of 26,282,827 outstanding ordinary shares.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six clinical and over 50 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to receive up to EUR3.3 billion in downstream milestones, plus royalties. The Galapagos Group has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More info at:

Cautionary note regarding forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

Contact Information


    Galapagos NV
    Onno van de Stolpe, CEO
    Tel: +31 6 2909 8028
    Email Contact

    Elizabeth Goodwin, Director Investor Relations
    Tel: +31 6 2291 6240
    Email Contact